Geode Capital Management LLC increased its stake in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 3.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 97,459 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,827 shares during the quarter. Geode Capital Management LLC’s holdings in ANI Pharmaceuticals were worth $4,387,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently made changes to their positions in ANIP. Investment Counselors of Maryland LLC increased its holdings in ANI Pharmaceuticals by 771.6% in the 4th quarter. Investment Counselors of Maryland LLC now owns 207,300 shares of the specialty pharmaceutical company’s stock valued at $9,333,000 after buying an additional 183,515 shares during the period. Dimensional Fund Advisors LP increased its holdings in ANI Pharmaceuticals by 6.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 511,881 shares of the specialty pharmaceutical company’s stock valued at $28,941,000 after buying an additional 32,556 shares during the period. Ontario Teachers Pension Plan Board bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at $1,241,000. Martingale Asset Management L P bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at $1,050,000. Finally, First Manhattan Co. increased its holdings in ANI Pharmaceuticals by 8.9% in the 4th quarter. First Manhattan Co. now owns 234,995 shares of the specialty pharmaceutical company’s stock valued at $10,579,000 after buying an additional 19,300 shares during the period. 59.75% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Arthur Przybyl sold 27,625 shares of the business’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $63.53, for a total value of $1,755,016.25. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Robert W. Schrepfer sold 4,651 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $64.43, for a total transaction of $299,663.93. Following the completion of the sale, the senior vice president now owns 53,484 shares in the company, valued at approximately $3,445,974.12. The disclosure for this sale can be found here. 33.10% of the stock is currently owned by insiders.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $1.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.24 by $0.08. ANI Pharmaceuticals had a net margin of 7.69% and a return on equity of 28.84%. The company had revenue of $57.12 million for the quarter, compared to the consensus estimate of $53.48 million. During the same quarter in the previous year, the company earned $1.08 EPS. The firm’s revenue for the quarter was up 20.8% compared to the same quarter last year. On average, sell-side analysts forecast that ANI Pharmaceuticals Inc will post 5.97 EPS for the current year.
Several brokerages have issued reports on ANIP. ValuEngine raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Cantor Fitzgerald set a $74.00 price target on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 28th. BidaskClub raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. TheStreet raised shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 19th. Finally, Raymond James set a $73.00 price target on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 28th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $73.25.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/24/geode-capital-management-llc-increases-position-in-ani-pharmaceuticals-inc-anip.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Article: Momentum Indicator: Relative Strength Index
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.